Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950607 · ClinicalTrials.gov registry record · NA
Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0
A NA study of Alzheimer Disease and Dementia, sponsored by Hebrew SeniorLife.
- Recruiting
- Registry status
- NA
- Development phase
- 750
- Enrollment target
- 1
- Study location
NCT05950607: Recruiting NA study of Alzheimer Disease and Dementia, sponsored by Hebrew SeniorLife.
NCT05950607 is a NA study of Alzheimer Disease and Dementia that is actively recruiting participants, run by Hebrew SeniorLife. The registered enrollment target is 750 participants, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05950607, a NA study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by Hebrew SeniorLife.
- RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pragmatic cluster randomized clinical trial is to compare management of suspected infection in nursing home residents with dementia The main questions it aims to answer whether residents with dementia in nursing homes randomized to use a multicomponent intervention to optimize suspected infection management ( versus usual care) use less antibiotics and fewer burdensome interventions.
Primary Outcome
Number of antimicrobial courses/person-year among residents with moderate to advanced dementia.
Conditions Studied
Interventions
- BEHAVIORAL TRAIN AD 2.0
Study Locations (1)
Massachusetts
- Hebrew SeniorLife - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05950607 shows while recruiting
NCT05950607 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which TRAIN AD 2.0 is the first listed.
NCT05950607 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05950607 about?
NCT05950607 is a clinical study titled "Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0". The goal of this pragmatic cluster randomized clinical trial is to compare management of suspected infection in nursing home residents with dementia The main questions it aims to answer whether residents with dementia in nursing homes randomized to use a multicomponent intervention to optimize suspe...
What is the current status of trial NCT05950607?
This trial is currently recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2023-11-13. Estimated completion is 2026-06-30.
What conditions does trial NCT05950607 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Infections.
What interventions are being tested in trial NCT05950607?
The interventions under investigation include: TRAIN AD 2.0 (BEHAVIORAL).
Who is sponsoring clinical trial NCT05950607?
This trial is sponsored by Hebrew SeniorLife, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05950607 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05950607's enrollment target sits among peer trials
750 40th of 306 higher than 267 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI